Bill Lundberg
Chief Executive Officer at MERUS N.V.
Net worth: 7 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samarth Kulkarni | M | 45 | 9 years | |
| V. Michael Holers | M | - |
Taligen Therapeutics, Inc.
 Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 9 years |
| Dave Grayzel | M | 56 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
| Mark Iwicki | M | 57 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 9 years |
| Jodie Morrison | F | 48 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 2 years |
| Stephen P. Squinto | M | 67 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 24 years |
| Peter Silverman | M | 46 | 7 years | |
| Bob Ang | M | 49 | 5 years | |
| Gregory Perry | M | 63 | 8 years | |
| Anand Mehra | M | 48 | 9 years | |
| Matt Patterson | M | 52 | 4 years | |
| Jonathan Terrett | M | - | 7 years | |
| Len Kanavy | M | 62 | 6 years | |
| Victor Sandor | M | 57 | 5 years | |
| Sarah Spencer | F | - | - | |
| Joshua Resnick | M | 49 | 5 years | |
| Daniella Beckman | F | 45 | 4 years | |
| Paolo Pucci | M | 63 | 4 years | |
| Jim Kasinger | M | 52 | 7 years | |
| David Lubner | M | 60 | 4 years | |
| Shelia Violette | M | - |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 7 years |
| Ali Behbahani | M | 47 | 9 years | |
| Simeon George | M | 46 | 9 years | |
| Sherri L. Spear | F | - | - | |
| Cecilia Anna Wilhelmina Geuijen | M | 56 | 3 years | |
| Ernesto Wasserman | M | - | 8 years | |
| Shannon Campbell | F | - | 2 years | |
| Kathleen Farren | F | - | - | |
| Tania Philipp | F | 52 | 5 years | |
| Ashley Pereira | M | - | 3 years | |
| Andrew Joe | M | 58 | 4 years | |
| Harry Shuman | M | - | - | |
| Tirtha Chakraborty | M | 51 | 4 years | |
| Eyal Attar | M | 53 | 2 years | |
| Nathan Jorgensen | M | 47 | 4 years | |
| Liu Hui | M | 51 | 9 years | |
| Simon Read | M | 53 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 3 years |
| John C. King | M | 49 | 4 years | |
| Megan Wherry Menner | F | - | 8 years | |
| Alexander Berthold Hendrik Bakker | M | 57 | 14 years | |
| Jason A. Campagna | M | 54 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
| Michael Gladstone | M | 37 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
| Maxine Gowen | M | 66 | 3 years | |
| Brian Gallagher | M | 54 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
| John de Kruif | M | 60 | 17 years | |
| Robert G. Pietrusko | M | 76 | 4 years | |
| Shelley Chu | M | 54 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | - |
| Kathy LaPorte | F | 62 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | 3 years |
| Sarah Marshall | F | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kush Parmar | M | 42 | 4 years | |
| Ton Logtenberg | M | 65 | 16 years | |
| Abbie Celniker | M | 65 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 3 years |
| Joseph A. Madri | M | 80 | 22 years | |
| David Brennan | M | 70 | 7 years | |
| Christopher Coughlin | M | 71 | 7 years | |
| Lawrence Klein | M | 41 | - | |
| Michael Tomsicek | M | 58 | 4 years | |
| Pablo Cagnoni | M | 60 | 4 years | |
| Mark Throsby | M | 57 | 12 years | |
| John Paul de Koning | M | 55 | 10 years | |
| Jack Mollen | M | 73 | 7 years | |
| Mark Day | M | 52 | 2 years | |
| Timothy C. Mills | M | 68 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
| Lisa Lejuwaan | F | - | - | |
| N. Coles | M | 63 | 2 years | |
| Larry L. Mathis | M | 80 | 10 years | |
| Kurt von Emster | M | 56 | 4 years | |
| Scott Peters | M | - | 8 years | |
| M. Burns | F | 66 | 4 years | |
| Max E. Link | M | 84 | 22 years | |
| James Woodruff Emlen | M | - |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 8 years |
| Sadik Kassim | M | - | 2 years | |
| Matthew DeLawder | M | - | 5 years | |
| Richard Riese | M | 61 | 3 years | |
| George Llado | M | 58 | - | |
| Thomas-Christian Mix | M | 57 | 2 years | |
| Christopher Slapak | M | 65 | 3 years | |
| Amy Mendel | F | 44 | 3 years | |
| Rebecca Velez Frey | F | - | 5 years | |
| John Miller | M | - | - | |
| Ted Harding | M | - | 1 years | |
| Behrad Derakhshan | M | 44 | 2 years | |
| Saqib Islam | M | 54 | 3 years | |
| Stephan Toutain | M | - | 2 years | |
| Christopher Horvath | M | - |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
| Patrice Coissac | M | 75 | 8 years | |
| Edward Hurwitz | M | 60 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | - |
| Thomas Dubin | M | 62 | 12 years | |
| Francis Wright | M | 76 | 2 years | |
| Martin MacKay | M | 68 | 4 years | |
| Warren W. Wasiewski | M | 71 | 2 years | |
| James Bilotta | M | - | 10 years | |
| Mittie Doyle | M | 59 | 3 years | |
| Thomas Bock | M | 60 | 3 years | |
| Jason Ryan | M | 49 |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | 2 years |
| Marc A. Becker | M | 52 | 1 years | |
| Julie O'Neill | F | 58 | 3 years | |
| Romesh R. Subramanian | M | 58 | 3 years | |
| Chris Erdman | M | - | 1 years | |
| Albert Paszek | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 66 | 66.00% |
| Netherlands | 22 | 22.00% |
| Switzerland | 13 | 13.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bill Lundberg
- Personal Network